Myriad Genetics, Inc. (MYGN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Myriad Genetics, Inc. (MYGN) trades at $5.92 with AI Score 14/100 (Grade F). Myriad Genetics, Inc. is a genetic testing and precision medicine company that develops and commercializes molecular diagnostic tests. Market cap: $559M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 8, 2026MYGN stock analysis for 2026: Analysts have set a consensus price target of $6.00 for Myriad Genetics, Inc., suggesting 1.4% upside from the current price of $5.92. The AI MoonshotScore is 14/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MYGN: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Myriad Genetics, Inc. (MYGN) Healthcare & Pipeline Overview
Myriad Genetics, Inc. specializes in genetic testing and precision medicine, providing molecular diagnostic tests for oncology, women's health, and mental health. With a focus on hereditary cancer risk assessment and personalized treatment strategies, Myriad operates in the competitive diagnostics market, leveraging strategic collaborations to expand its testing services.
What Is the Investment Thesis for MYGN?
Myriad Genetics operates in the growing precision medicine market, with a focus on genetic testing for cancer, women's health, and mental health. The company's gross margin of 70.0% indicates strong pricing power and efficient operations. Key growth catalysts include expanding adoption of its MyRisk Hereditary Cancer Test and BRACAnalysis CDx. The company's strategic collaborations with Illumina and Intermountain Precision Genomics could drive further market penetration. However, a profit margin of -48.2% raises concerns about profitability and cost management. Investors should monitor the company's ability to achieve sustainable profitability and manage its operating expenses effectively.
Based on FMP financials and quantitative analysis
MYGN Key Highlights
- Market Cap of $559M reflects its current valuation in the genetic testing market.
- Gross Margin of 70.0% demonstrates strong pricing power and efficient cost management in its testing services.
- Profit Margin of -48.2% indicates ongoing challenges with profitability and expense management.
- Beta of 1.64 suggests higher volatility compared to the broader market.
- Strategic collaborations with Illumina and Intermountain Precision Genomics enhance its market reach and service capabilities.
Who Are MYGN's Competitors?
MYGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ILMN Illumina, Inc. | $184.68 | -1.06% | $27.9B | 91 |
| PRE Prenetics Global Limited | $20.02 | +9.45% | $340M | 69 |
| EDTXF Spectral Medical Inc. | $1.00 | -0.99% | $293M | 56 |
| OPGN OpGen, Inc. | $23.91 | +64.36% | $243M | 63 |
| PFGTF Pacific Edge Limited | $0.17 | +0.00% | $212M | 52 |
| DIUXF Diaceutics PLC | $2.00 | +0.00% | $169M | 59 |
| GTH Genetron Holdings Limited | $4.03 | +0.12% | $127M | 61 |
| CORBF Global Cord Blood Corporation | $0.95 | +0.00% | $127M | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MYGN's Key Strengths?
- Diverse portfolio of genetic tests.
- Established presence in oncology, women's health, and mental health.
- Strategic collaborations with industry leaders.
- Proprietary technology and intellectual property.
What Are MYGN's Weaknesses?
- Negative profit margin.
- High beta indicating higher volatility.
- Dependence on reimbursement policies.
- Competition from larger diagnostic companies.
What Could Drive MYGN Stock Higher?
- Expansion of MyRisk Hereditary Cancer Test into new markets.
- Increased adoption of BRACAnalysis CDx in metastatic cancer treatment.
- Growth in mental health testing with GeneSight.
- Strategic collaborations with Illumina and Intermountain Precision Genomics.
What Are the Key Risks for MYGN?
- Financial-distress signal — its Altman Z-Score of -1.75 sits in the distress zone (elevated bankruptcy risk).
- Changes in reimbursement policies impacting test pricing.
- Competition from lower-cost providers.
- Patent expirations affecting key products.
- Regulatory hurdles and compliance requirements.
What Are the Growth Opportunities for MYGN?
- Expansion of MyRisk Hereditary Cancer Test: Myriad Genetics can drive growth by expanding the adoption of its MyRisk Hereditary Cancer Test. The hereditary cancer testing market is growing as awareness of genetic predispositions increases. By targeting specific demographics and collaborating with healthcare providers, Myriad can increase test volumes and revenue.
- Increased Adoption of BRACAnalysis CDx: The BRACAnalysis CDx Germline Companion Diagnostic Test offers a significant growth opportunity. As personalized medicine becomes more prevalent, the demand for companion diagnostic tests to guide treatment decisions will increase. By demonstrating the clinical utility and cost-effectiveness of BRACAnalysis CDx, Myriad can drive adoption among oncologists and patients. This test addresses a critical need in the treatment of metastatic cancers, positioning Myriad as a key player in precision oncology.
- Growth in Mental Health Testing with GeneSight: Myriad Genetics can capitalize on the growing demand for mental health testing with its GeneSight Psychotropic Mental Health Medication Test. The market for pharmacogenomic testing in mental health is expanding as healthcare providers seek to optimize treatment outcomes. By demonstrating the value of GeneSight in improving medication selection and reducing adverse effects, Myriad can drive adoption among psychiatrists and primary care physicians. The increasing prevalence of mental health disorders presents a substantial market opportunity.
- Strategic Collaborations for Expanded Services: Myriad Genetics' strategic collaborations with Illumina, Inc. and Intermountain Precision Genomics offer opportunities for expanded services and market reach. By leveraging these partnerships, Myriad can offer a broader range of germline and somatic tumor testing services. These collaborations can also facilitate access to new markets and customer segments. The synergies created through these partnerships can drive revenue growth and enhance Myriad's competitive position.
- Penetration of the Prenatal Screening Market: Myriad Genetics can further penetrate the prenatal screening market with its Prequel Prenatal Screen and Foresight Carrier Screen. The demand for non-invasive prenatal screening is increasing as expectant parents seek to assess the risk of chromosomal disorders and genetic conditions. By offering accurate and reliable prenatal screening tests, Myriad can capture a larger share of this market. The prenatal screening market is expected to continue growing, driven by technological advancements and increasing awareness among parents.
What Opportunities Does MYGN Have?
- Expansion into new geographic markets.
- Development of new genetic tests for emerging diseases.
- Increased adoption of precision medicine.
- Growing demand for prenatal screening.
What Threats Does MYGN Face?
- Changes in reimbursement policies.
- Competition from lower-cost providers.
- Patent expirations.
- Regulatory hurdles.
What Are MYGN's Competitive Advantages?
- Proprietary genetic tests with patent protection.
- Established brand reputation in genetic testing.
- Strategic collaborations with key industry players.
- Extensive database of genetic information.
- Specialized expertise in molecular diagnostics.
What Does MYGN Do?
Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics, Inc. has evolved into a leading genetic testing and precision medicine company. The company develops and commercializes a range of molecular diagnostic tests, primarily focusing on oncology, women's health, and mental health. Its offerings include the MyRisk Hereditary Cancer Test, which assesses risks for hereditary cancers through DNA sequencing, and the BRACAnalysis CDx Germline Companion Diagnostic Test, which helps determine therapy for patients with specific metastatic cancers. Myriad also provides the MyChoice CDx Companion Diagnostic Test for ovarian cancer patients. In addition to oncology-focused tests, Myriad offers the Prolaris Prostate Cancer Prognostic Test and the EndoPredict Breast Cancer Prognostic Test, both RNA expression tumor analyses. The company's portfolio extends to prenatal screening with the Prequel Prenatal Screen and the Foresight Carrier Screen. GeneSight Psychotropic Mental Health Medication Test aids in psychotropic drug selection. Myriad Genetics collaborates with Illumina, Inc. and Intermountain Precision Genomics to broaden its germline and somatic tumor testing services, enhancing its market reach and service capabilities.
What Products and Services Does MYGN Offer?
- Develops and commercializes genetic tests.
- Offers molecular diagnostic tests for oncology.
- Provides tests for women's health applications.
- Offers tests for mental health applications.
- Provides hereditary cancer risk assessment through DNA sequencing.
- Offers companion diagnostic tests to guide cancer therapy decisions.
- Provides prenatal screening tests for chromosomal disorders.
- Offers pharmacogenomic testing for mental health medication selection.
How Does MYGN Make Money?
- Develops proprietary genetic tests.
- Commercializes tests through direct sales and partnerships.
- Generates revenue from test orders.
- Collaborates with other companies for research and development.
What Industry Does MYGN Operate In?
Myriad Genetics operates within the medical diagnostics and research industry, which is experiencing growth driven by advancements in genetic sequencing and personalized medicine. The market is competitive, with companies offering a range of diagnostic tests for various diseases. Key trends include the increasing adoption of precision medicine approaches and the growing demand for genetic testing in oncology and prenatal care. Myriad Genetics competes with other diagnostic companies by offering specialized tests and leveraging strategic collaborations to expand its market presence.
Who Are MYGN's Key Customers?
- Oncologists and cancer patients.
- Women's health specialists and expectant parents.
- Psychiatrists and mental health patients.
- Hospitals and clinics.
- Research institutions.
How Myriad Genetics, Inc. Is Valued
Relative to its peer group, MYGN's quantitative score of 14/100 is below the peer average of 66/100.
Company Profile
Myriad Genetics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Samraat S Raha. MYGN has traded publicly since 1995.
F-Score 5/9Financial Health
Myriad Genetics, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.75 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Myriad Genetics, Inc. revenue of about $863.6M for fiscal 2026, with EPS near $0.06. The estimate reflects 6 contributing analysts.
MYGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diverse portfolio of genetic tests.
- Established presence in oncology, women's health, and mental health.
- Strategic collaborations with industry leaders.
- Proprietary technology and intellectual property.
Bear Case
- Negative profit margin.
- High beta indicating higher volatility.
- Dependence on reimbursement policies.
- Competition from larger diagnostic companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MYGN Latest News
-
Stocks That Hit 52-Week Highs On Wednesday
· Feb 3, 2021
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
MYGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MYGN.
Price Targets
Consensus target: $6.00
MYGN MoonshotScore
What does this score mean?
The MoonshotScore rates MYGN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Samraat S. Raha
CEO
Samraat S. Raha serves as the CEO of Myriad Genetics, Inc. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining Myriad, Raha held leadership positions at various healthcare companies, focusing on strategic growth and operational efficiency. His expertise spans across commercial operations, product development, and market access. Raha's experience positions him to lead Myriad Genetics in a competitive and evolving market landscape.
Track Record: Since assuming the role of CEO, Samraat S. Raha has focused on driving growth and improving profitability at Myriad Genetics. Key initiatives include expanding the company's product portfolio, strengthening strategic collaborations, and optimizing operational efficiency. Under his leadership, Myriad has continued to innovate in the field of genetic testing and precision medicine.
What Investors Ask About Myriad Genetics, Inc. (MYGN) — Healthcare
What does the AI Score mean for MYGN?
MYGN holds an AI Score of 14/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Myriad Genetics, Inc. is a genetic testing and precision medicine company that develops and commercializes molecular diagnostic tests. The company focuses on oncology, women's health, and mental …
What does Myriad Genetics, Inc. do?
Myriad Genetics, Inc. is a genetic testing and precision medicine company that develops and commercializes molecular diagnostic tests for oncology, women's health, and mental health. The company offers a range of tests, including MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and GeneSight Psychotropic Mental Health Medication Test.
What do analysts say about MYGN stock?
Analyst coverage of Myriad Genetics (MYGN) reflects a mixed outlook, with some emphasizing the company's growth potential in precision medicine and others highlighting concerns about profitability and competition. Key valuation metrics include the company's market capitalization and price-to-sales ratio. Growth considerations include the adoption of Myriad's genetic tests, strategic collaborations, and market expansion efforts.
What are the main risks for MYGN?
Myriad Genetics faces several risks, including changes in reimbursement policies, competition from lower-cost providers, patent expirations, and regulatory hurdles. Changes in reimbursement policies could impact the pricing and adoption of Myriad's genetic tests. Competition from other diagnostic companies could erode market share and pricing power. Patent expirations could lead to generic competition and reduced revenue.
What are the key factors to evaluate for MYGN?
Myriad Genetics, Inc. (MYGN) holds an AI score of 14/100 (low). Analysts target $6.00 (+1%). Not financial advice.
How frequently does MYGN data refresh on this page?
MYGN's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MYGN's recent stock price performance?
Myriad Genetics, Inc. (MYGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse portfolio of genetic tests. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MYGN overvalued or undervalued right now?
Myriad Genetics, Inc. (MYGN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $6.00 (+1%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MYGN before investing?
Before investing in Myriad Genetics, Inc. (MYGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be subject to change.
- Market conditions can impact company performance.
- This is not investment advice.